Back Hepatitis C

Hepatitis C

EASL Paris: AbbVie 3D Regimen for 8 Weeks Cures Almost All HCV Genotype 1b Patients

AbbVie's paritaprevir-based 3D regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat non-cirrhotic patients with hepatitis C virus (HCV) genotype 1b, according to findings from the GARNET study, presented last week at the EASL special conference New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.

alt

EASL Paris: 100% Cure Rate with AL-335, Odalasvir, and Simeprevir for 6 or 8 Weeks

A triple regimen containing 2 experimental hepatitis C drugs -- AL-335 and odalasvir -- plus simeprevir taken for either 6 or 8 weeks cured all previously untreated, non-cirrhotic patients with HCV genotype 1 in a small study, while a dual regimen without simeprevir cured 90%, according to findings presented last week at the EASL special conference New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.

alt

INHSU 2016: HCV Treatment Effective and May Work as Prevention for People Who Inject Drugs

Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users -- with cure rates exceeding 90% -- and treating enough of this population could reduce transmission or even bring a halt to local epidemics, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo.

alt

STD 2016: HCV Infection and Reinfection Among Men Who Have Sex with Men

Public health officials in Michigan have identified a cluster of more than 20 cases of apparently sexually transmitted hepatitis C virus (HCV) infection among HIV-positive gay and bisexual men, according to a report at the 2016 STD Conference last week in Atlanta. Routine HCV screening at sexual health clinics can help detect more HCV infections among gay men, and prevention measures are needed to address the risk of HCV reinfection after spontaneous clearance or a cure, researchers concluded in recent related journal articles.

alt

INHSU 2016: Hepatitis C Vaccine Development Shows Progress but Scientific Barriers Remain

An effective vaccine may be necessary to eliminate hepatitis C virus (HCV), but development has been hampered by several challenges including the variability of the virus and incomplete natural immunity, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo. One promising prime-boost viral vector vaccine is currently in clinical trials.

alt

EASL Issues New Hepatitis C Treatment Recommendations For All Genotypes

The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last week in Paris. The updated guidelines now include highly effective interferon-free options for all hepatitis C virus (HCV) genotypes and for the most challenging patients.

alt

INHSU 2016: Scaling Up Treatment in Prisons Could Help Halt Hepatitis C Epidemics

A substantial proportion of people with hepatitis C cycle through the criminal justice system, making prisons one of the most important settings for hepatitis C virus (HCV) prevention, testing, and treatment. Scaling up treatment could therefore play a major role in driving down HCV prevalence and curbing hepatitis C epidemics worldwide, according to studies presented at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this week in Oslo.

alt

INHSU 2016: Risk of Reinfection Is a Concern After Successful Hepatitis C Treatment

People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) -- achieving cure rates similar to those of the population as a whole -- but some people are reinfected with hepatitis C virus after being cured, suggesting that a greater emphasis on post-treatment prevention may be needed, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this month in Oslo.

alt

INHSU 2016: Effective Antiviral Treatment Reduces Fatigue in People with Hepatitis C

Fatigue -- a common symptom among people living with hepatitis C virus (HCV) infection -- is associated with liver inflammation and fibrosis, but antiviral therapy that leads to a cure significantly reduces the likelihood of fatigue, according to a Danish study presented at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this week in Oslo.

alt